Stock PPBT PURPLE BIOTECH LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Purple Biotech Ltd Nasdaq

Equities

PPBT

US74638P1093

Real-time Estimate Cboe BZX
Other stock markets
 14:56:08 2024-05-31 EDT 		5-day change 1st Jan Change
0.968 USD +13.27% Intraday chart for Purple Biotech Ltd +35.57% +29.49%
04-25 Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting CI
03-14 Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Purple Biotech Reports First Quarter 2024 Financial Results
AQ
Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
CI
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
AQ
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology
CI
Purple Biotech : Immediate Report
PU
6K:Fourth Quarter and Full-Year 2023 Financial Results
PU
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
AQ
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024
CI
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
AQ
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
AQ
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
CI
Purple Biotech Ltd. Announces Executive Changes
CI
Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
CI
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
AQ
Papillary Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Purple Biotech Reports Third Quarter 2023 Financial Results
AQ
Purple Biotech Fortifies NT219 Patent Protection
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PPBT Stock
  4. PPBT Stock
  5. News Purple Biotech Ltd